The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through ...

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...

Over his eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company said. However, the shares ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down as the company faces challenges in the obesity drug market, which ...